Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Myeloid 2Lymphoid 2

Conditions

Leukemia, Myeloid, Acute 10Mastocytosis, Systemic 3Leukemia, Mast-Cell 2Aggression 2Recurrence 1Myelodysplastic Syndromes 1Mastocytosis 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leukemia, Biphenotypic, Acute 1Leukemia 1Congenital Abnormalities 1Blast Crisis 1

Interventions

fludarabine phosphate 3midostaurin 2Whole-Body Irradiation 2Therapeutics 2Mycophenolic Acid 2Methotrexate 2Cyclosporine 2Busulfan 2thymoglobulin 1ibrutinib 1hydrocortisone valerate 1fludarabine 1denileukin diftitox 1avapritinib 1Thiotepa 1Tacrolimus 1Sunitinib 1Rituximab 1Peripheral Blood Stem Cell Transplantation 1Methylprednisolone Hemisuccinate 1Methylprednisolone Acetate 1Methylprednisolone 1Leucovorin 1Imatinib Mesylate 1Hydrocortisone 1Granulocyte Colony-Stimulating Factor 1Granisetron 1Filgrastim 1Epoetin Alfa 1Enzyme-Linked Immunosorbent Assay 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Leukemia, Mast-Cell × midostaurin × Clear all
NCT00782067 2018-11-15

Efficacy and Safety of Midostaurin in Patients With Aggressive Systemic Mastocytosis or Mast Cell Leukemia

Novartis

Phase 2 Completed
116 enrolled 16 charts
LymphoidMyeloidOther hematologic neoplasm

Aggression, Leukemia, Leukemia, Mast-Cell, Mastocytosis, Systemic

NCT00233454 2018-09-20

Phase 2 Midostaurin in Aggressive Systemic Mastocytosis and Mast Cell Leukemia

Stanford University

Phase 2 Completed
26 enrolled 12 charts
LymphoidMyeloidOther hematologic neoplasm

Aggression, Leukemia, Mast-Cell, Mastocytosis, Systemic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡